Syndax Pharmaceuticals (SNDX) Research & Development (2015 - 2026)

Syndax Pharmaceuticals' Research & Development history runs 12 years deep, the most recent figure standing at $58.8 million for Q1 2026.

• In Q1 2026, Research & Development fell 4.53% year-over-year to $58.8 million; the TTM figure through Mar 2026 stood at $256.0 million (up 34.15% YoY), while the FY2025 annual figure was $258.8 million, up 7.09% from the prior year.
• Research & Development was $58.8 million for Q1 2026 at Syndax Pharmaceuticals, down from $78.6 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $78.6 million in Q4 2025 to a low of $15.0 million in Q3 2024.
• Historically, Research & Development has averaged $45.4 million across 5 years, with a median of $48.7 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Research & Development surged 1401.1% in 2022, then tumbled 61.62% in 2024.
• A 5-year view of Research & Development shows it stood at $31.8 million in 2022, then surged by 73.13% to $55.1 million in 2023, then grew by 18.87% to $65.5 million in 2024, then gained by 20.01% to $78.6 million in 2025, then dropped by 25.17% to $58.8 million in 2026.
• The last three Research & Development figures came in at $58.8 million (Q1 2026), $78.6 million (Q4 2025), and $56.3 million (Q3 2025), per Business Quant data.